Anivance AI

Anivance AI is reshaping preclinical research with a fully integrated, animal-free platform aligned with the U.S. FDA’s 2025 roadmap for New Approach Methodologies (NAMs). We accelerate safer, faster drug development by combining organ-on-chip technology, high-throughput phenotypic profiling, and predictive AI. Our platform delivers insights across cancer, lung diseases, rare conditions, and advanced drug delivery — replacing animal models with human-relevant, scalable systems. We’ve built validated models for the lung, liver, heart, kidney, and tumors, partnering with 50+ physicians and 6 clinical institutions worldwide. Backed by Taiwan’s largest tech firms, Anivance holds 25 patents and was nominated for the LUSH Prize in Science. We pioneer a “No Animals, No Delays, Just Human Data” vision.